Stryker Corporation announced today that after 30 years of distinguished service, Lonny Carpenter, Group President, Global Quality and Business Operations has notified the Company of his intent to retire on March 31, 2019.
Mr. Carpenter will transfer his responsibility for Global Quality and Operations to Viju Menon, as outlined below, and retain responsibilities for our regional business operations outside of the U.S. and Asia-Pacific. He will also remain involved with our Cost Transformation for Growth program.
Mr. Carpenter began his career with Stryker in 1989 at the Instruments division where he excelled in various manufacturing and operations roles. He then proceeded to take on numerous operations and commercial business roles across the Company, including President of Medical and Group President, Instruments and Medical. In 2011, he became Group President, Global Quality and Operations and in 2014, his role was expanded to include responsibility for commercial business operations in Europe, Middle East, Africa, Canada, and Latin America.
“We are grateful for Lonny’s many contributions to Stryker’s growth and globalization efforts over the last three decades. He has been the key architect of numerous change initiatives, including our Quality Program, the establishment of our Trans-Atlantic Operating Model and Cost Transformation for Growth. He is a master collaborator and embodies our culture and values. I wish Lonny and his family all the best on his retirement,” said Kevin A. Lobo, Chairman and Chief Executive Officer.
Viju Menon will be joining Stryker as Group President, Global Quality and Operations, effective April 30, 2018. He will be responsible for running our quality, manufacturing, procurement and logistics organizations. He will work closely with Lonny to help ensure a smooth transition. “I am pleased that Viju will be joining the Stryker Leadership Team. His vast experience and technology background will complement our team and help drive Stryker’s continued growth,” said Mr. Lobo.
Mr. Menon joins us from Verizon where he served as Chief Supply Chain Officer, driving significant transformations in global sourcing and operations across all business units. Previously, in his career with Intel Corporation, Viju progressed through various leadership roles in Technology and Manufacturing and served as Head of Supply Planning Operations across Intel’s global factory network.
Mr. Menon earned dual graduate degrees (MBA and M.S. in Electrical Engineering) from the Massachusetts Institute of Technology’s Leaders for Global Operations Program. He also earned a graduate degree (M.S.E. in Computer Science Engineering) from the University of Michigan.
Source: Stryker
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.
